Latest Commercial Readiness News

Castile Resources has kicked off pilot plant bench scale testing for its Rover 1 project, integrating a 41% resource upgrade and higher metal prices into its Bankable Feasibility Study. The company also secured $8.4 million in funding and is preparing for exploration drilling amid regional consolidation.

Radiopharm Theranostics (ASX: RAD) has completed enrolment in its Phase 2b RAD 101 brain metastases imaging trial with interim data showing 90% concordance with MRI, while progressing early-stage trials of therapeutic candidates RAD 202, RV-01, and RAD 402. The company reported a $19.2 million cash balance at quarter end, down from $34.5 million, with a net operating cash outflow of $14.9 million driven by milestone-related R&D and staff costs.

Hazer Group has completed a key Process Design Package with KBR, unlocking large-scale commercial potential for its methane pyrolysis technology. The company also signed a non-binding graphite offtake LOI with Green Steel WA and qualified its graphite for concrete and asphalt applications, all while maintaining a solid cash position and reducing cash burn.

BlinkLab has secured A$17.5 million through an oversubscribed placement to fuel regulatory trials and commercial launch of its AI-driven autism and ADHD diagnostic tools.

Iondrive Limited has confirmed over 90% extraction of key rare earth elements neodymium and praseodymium from US commercial samples, exceeding prior economic assumptions and advancing its modular recycling technology toward commercial deployment.

Vysarn Limited's joint venture with Kariyarra Aboriginal Corporation has been shortlisted by Water Corporation to submit a formal proposal for supplying bulk water to Port Hedland, progressing key regulatory approvals for the Kariyarra Water Scheme.

Metal Powder Works has independently confirmed its DirectPowder™ CP Titanium Grade 2 feedstock meets stringent ASTM B384 structural standards via Laser Powder Bed Fusion, reinforcing its position in aerospace additive manufacturing.

Nexsen Limited's subsidiary has won a HK$6 million grant to accelerate clinical validation and manufacturing of its rapid Group B Streptococcus diagnostic in Hong Kong, positioning the city as a key Asia-Pacific hub.

Cleo Diagnostics has expanded its ovarian cancer biomarker panel from five to eight markers, enhancing test reliability and gearing up for FDA submission. A manufacturing deal is imminent, setting the stage for commercial rollout.

Nexsen Limited has successfully completed a pivotal FDA Pre-Submission meeting for its StrepSure® diagnostic, significantly reducing regulatory risks and advancing its entry into the large US maternal health market.

Provaris Energy reported a 59% increase in its half-year loss to $2.09 million, driven by higher project development costs amid progress in hydrogen and carbon capture technologies. The company raised over $3.5 million in capital and is advancing key milestones for its hydrogen shipping and liquid CO2 tank projects.

Paradigm Biopharmaceuticals has drawn down US$5 million from its Convertible Note Facility to fund the next phase of its global Phase 3 trial for knee osteoarthritis treatment, marking a key step as patient recruitment nears 50%.